Dihydrosphingolipids are associated with steatosis and increased fibrosis damage in non-alcoholic fatty liver disease.

[1]  B. Neuschwander‐Tetri,et al.  Prospective Study of Outcomes in Adults with Nonalcoholic Fatty Liver Disease. , 2021, The New England journal of medicine.

[2]  A. Shevchenko,et al.  Nonalcoholic fatty liver disease stratification by liver lipidomics , 2021, Journal of lipid research.

[3]  M. Maceyka,et al.  Sphingolipids in metabolic disease: The good, the bad, and the unknown. , 2021, Cell metabolism.

[4]  S. Friedman,et al.  Mechanisms and disease consequences of nonalcoholic fatty liver disease , 2021, Cell.

[5]  Ó. Pastor,et al.  A normalized signal calibration with a long-term reference improves the robustness of RPLC-MRM/MS lipidomics in plasma , 2021, Analytical and Bioanalytical Chemistry.

[6]  P. Meikle,et al.  Hepatic lipidomic remodeling in severe obesity manifests with steatosis and does not evolve with non-alcoholic steatohepatitis. , 2021, Journal of hepatology.

[7]  S. Hunt,et al.  Characterizing a common CERS2 polymorphism in a mouse model of metabolic disease and in subjects from the Utah CAD Study. , 2021, The Journal of clinical endocrinology and metabolism.

[8]  F. Foufelle,et al.  Roles of Ceramides in Non-Alcoholic Fatty Liver Disease , 2021, Journal of clinical medicine.

[9]  A. Hartemann,et al.  Dihydroceramides in Triglyceride-Enriched VLDL Are Associated with Nonalcoholic Fatty Liver Disease Severity in Type 2 Diabetes , 2020, Cell reports. Medicine.

[10]  Sohee Oh,et al.  Circulating lipidomic alterations in obese and non‐obese subjects with non‐alcoholic fatty liver disease , 2020, Alimentary pharmacology & therapeutics.

[11]  Y. Hannun,et al.  Targeting acid ceramidase inhibits YAP/TAZ signaling to reduce fibrosis in mice , 2020, Science Translational Medicine.

[12]  Chih-Chiang Chan,et al.  Dihydroceramide desaturase regulates the compartmentalization of Rac1 for neuronal oxidative stress , 2020, bioRxiv.

[13]  V. Wong,et al.  A new definition for metabolic associated fatty liver disease: an international expert consensus statement. , 2020, Journal of hepatology.

[14]  S. Summers,et al.  DES1: A Key Driver of Lipotoxicity in Metabolic Disease. , 2020, DNA and cell biology.

[15]  G. Shulman,et al.  Nonalcoholic Fatty Liver Disease, Insulin Resistance, and Ceramides. , 2019, The New England journal of medicine.

[16]  Min Hee Kim,et al.  Hepatic triglyceride accumulation via endoplasmic reticulum stress-induced SREBP-1 activation is regulated by ceramide synthases , 2019, Experimental & Molecular Medicine.

[17]  S. Summers,et al.  Metabolic Messengers: ceramides , 2019, Nature Metabolism.

[18]  Sibali Bandyopadhyay,et al.  Analysis of 1-deoxysphingoid bases and their N-acyl-metabolites, and exploration of their occurrence in some food materials. , 2019, Journal of agricultural and food chemistry.

[19]  Aimin Wang,et al.  Inhibiting Ceramide Synthesis Attenuates Hepatic Steatosis and Fibrosis in Rats With Non-alcoholic Fatty Liver Disease , 2019, Front. Endocrinol..

[20]  James E. Cox,et al.  Targeting a ceramide double bond improves insulin resistance and hepatic steatosis , 2019, Science.

[21]  T. Langer,et al.  CerS6-Derived Sphingolipids Interact with Mff and Promote Mitochondrial Fragmentation in Obesity , 2019, Cell.

[22]  D. Schuppan,et al.  Mouse Models of Nonalcoholic Steatohepatitis: Toward Optimization of Their Relevance to Human Nonalcoholic Steatohepatitis , 2019, Hepatology.

[23]  H. Hermanns,et al.  Animal models of NAFLD from a hepatologist's point of view. , 2019, Biochimica et biophysica acta. Molecular basis of disease.

[24]  P. J. Larsen,et al.  The role of C16:0 ceramide in the development of obesity and type 2 diabetes: CerS6 inhibition as a novel therapeutic approach , 2019, Molecular metabolism.

[25]  S. Friedman,et al.  A simple diet- and chemical-induced murine NASH model with rapid progression of steatohepatitis, fibrosis and liver cancer. , 2018, Journal of hepatology.

[26]  F. Goñi,et al.  The Physical Properties of Ceramides in Membranes. , 2018, Annual review of biophysics.

[27]  K. Nadeau,et al.  Fructose and sugar: A major mediator of non-alcoholic fatty liver disease. , 2018, Journal of hepatology.

[28]  M. Roden,et al.  Specific Hepatic Sphingolipids Relate to Insulin Resistance, Oxidative Stress, and Inflammation in Nonalcoholic Steatohepatitis , 2018, Diabetes Care.

[29]  Michael Charlton,et al.  The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases , 2018, Hepatology.

[30]  R. Goldschmeding,et al.  Uncovering a Predictive Molecular Signature for the Onset of NASH-Related Fibrosis in a Translational NASH Mouse Model , 2017, Cellular and molecular gastroenterology and hepatology.

[31]  K. Kang,et al.  Dihydroceramide is a key metabolite that regulates autophagy and promotes fibrosis in hepatic steatosis model. , 2017, Biochemical and biophysical research communications.

[32]  Kim Ekroos,et al.  Reporting of lipidomics data should be standardized. , 2017, Biochimica et biophysica acta. Molecular and cell biology of lipids.

[33]  S. Subramanian,et al.  Cholesterol crystallization within hepatocyte lipid droplets and its role in murine NASH[S] , 2017, Journal of Lipid Research.

[34]  Y. Hannun,et al.  Ceramide Is Metabolized to Acylceramide and Stored in Lipid Droplets. , 2017, Cell metabolism.

[35]  V. Shah,et al.  Inhibition of sphingosine 1-phosphate signaling ameliorates murine nonalcoholic steatohepatitis. , 2017, American journal of physiology. Gastrointestinal and liver physiology.

[36]  Ioannis Xenarios,et al.  Plasma Dihydroceramides Are Diabetes Susceptibility Biomarker Candidates in Mice and Humans. , 2017, Cell reports.

[37]  S. Ima-Nirwana,et al.  Animal models of metabolic syndrome: a review , 2016, Nutrition & Metabolism.

[38]  L. Henry,et al.  Global epidemiology of nonalcoholic fatty liver disease—Meta‐analytic assessment of prevalence, incidence, and outcomes , 2016, Hepatology.

[39]  M. Orešič,et al.  Ceramides Dissociate Steatosis and Insulin Resistance in the Human Liver in Non-Alcoholic Fatty Liver Disease Short title : Ceramides in Human Non-Alcoholic Fatty Liver Disease , 2016 .

[40]  A. Sanyal,et al.  Drug-induced fatty liver disease: An overview of pathogenesis and management. , 2015, Annals of hepatology.

[41]  E. Bjornsson,et al.  Liver Fibrosis, but No Other Histologic Features, Is Associated With Long-term Outcomes of Patients With Nonalcoholic Fatty Liver Disease. , 2015, Gastroenterology.

[42]  Jonathan D. Smith,et al.  Ceramide as a Mediator of Non-Alcoholic Fatty Liver Disease and Associated Atherosclerosis , 2015, PloS one.

[43]  S. Summers,et al.  CerS2 haploinsufficiency inhibits β-oxidation and confers susceptibility to diet-induced steatohepatitis and insulin resistance. , 2014, Cell metabolism.

[44]  T. Hibi,et al.  Free cholesterol accumulation in hepatic stellate cells: Mechanism of liver fibrosis aggravation in nonalcoholic steatohepatitis in mice , 2014, Hepatology.

[45]  S. Terai,et al.  Hepatic Crown-Like Structure: A Unique Histological Feature in Non-Alcoholic Steatohepatitis in Mice and Humans , 2013, PloS one.

[46]  F. Bellanti,et al.  Free radical biology for medicine: learning from nonalcoholic fatty liver disease. , 2013, Free radical biology & medicine.

[47]  T. Roskams,et al.  Hepatic fat loss in advanced nonalcoholic steatohepatitis: Are alterations in serum adiponectin the cause? , 2013, Hepatology.

[48]  Steven Nusinowitz,et al.  Identification of DES1 as a Vitamin A Isomerase in Müller Glial Cells of the Retina , 2012, Nature chemical biology.

[49]  Joan Tordjman,et al.  Histopathological algorithm and scoring system for evaluation of liver lesions in morbidly obese patients , 2012, Hepatology.

[50]  Y. Hannun,et al.  Dihydroceramide desaturase activity is modulated by oxidative stress. , 2010, The Biochemical journal.

[51]  B. Kahn,et al.  Long-term Fenretinide treatment prevents high-fat diet-induced obesity, insulin resistance, and hepatic steatosis. , 2009, American journal of physiology. Endocrinology and metabolism.

[52]  Sofianos Andrikopoulos,et al.  Evaluating the glucose tolerance test in mice. , 2008, American journal of physiology. Endocrinology and metabolism.

[53]  J. Goldstein,et al.  Selective versus total insulin resistance: a pathogenic paradox. , 2008, Cell metabolism.

[54]  A. Vigé,et al.  C57BL/6J and A/J Mice Fed a High‐Fat Diet Delineate Components of Metabolic Syndrome , 2007, Obesity.

[55]  K. Zatloukal,et al.  From Mallory to Mallory-Denk bodies: what, how and why? , 2007, Experimental cell research.

[56]  M. Pfaffl,et al.  A new mathematical model for relative quantification in real-time RT-PCR. , 2001, Nucleic acids research.

[57]  J. Folch,et al.  A simple method for the isolation and purification of total lipides from animal tissues. , 1957, The Journal of biological chemistry.